Aquinox raises $18M in series C

Aquinox Pharmaceuticals Inc. (Vancouver, B.C.) raised US$18 million in a series C round led by existing investor Johnson & Johnson Development Corp. New investor Augment Investments also participated, along with existing investors Pfizer Venture Investments; Ventures West; and Baker Brothers. This quarter, Aquinox plans to start two Phase II trials of lead compound AQX-1125 to treat chronic obstructive pulmonary disease (COPD) and interstitial cystitis/bladder pain syndrome (IC/BPS). AQX-1125 is an SH2-containing inositol 5'-phosphatase (SHIP) agonist. ...